Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPOLOGY
2022-501507-27-00Phase 2Completed
- Sponsor
- Institut Curie
- Start
- Oct 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PLX038 in triple-negative breast cancer (TNBC), sponsored by Institut Curie. Primary endpoint: Best tumor response in first 6 months. Started Oct 2023; status: completed.
02
Drugs
PLX038
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-501507-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501507-27-00.